Impact of Zona Opening on Day 3 Preimplantation Embryos on Clinical Pregnancy Rates in a Private Clinic Devoted to Assisted Reproductive Technology

AbstractBackgroundWhile the assisted reproductive technology (ART) relieves the burden of infertility in many couples, it presents significant public health challenges due to the substantial risk for multiple birth delivery and preterm birth, which are associated with poor maternal and fetal health outcomes. For this reason, it is important to monitor the development and effectiveness of ART services in Thailand.ObjectiveTo analyze the trends of ART services in Thailand between 2008 and 2014.MethodsART clinics in Thailand are required to submit data to the Royal Thai College of Obstetricians and Gynecologists via the National Reporting System. The data from 2008 to 2014 were collected and analyzed.ResultsThe number of ART centers was increased from 35 to 47. The total fresh ART cycles were also increased from 3,723 to 6,516. The percentage values of intracytoplasmic sperm injection (ICSI), in vitro fertilization, gamete intrafallopian transfer, and zygote intrafallopian transfer cycles were changed from 77.87 to 95.59, 21.43 to 4.31, 0.21 to 0.09, and 0.45 to 0.05, respectively. The clinical pregnancy rates were 28.79–33.19, 22.84–51.34, 14.29–42.86, and 0.00–26.67, respectively. The clinical pregnancy rates in fresh vs. frozen-thawed cycles were 31.01–36.33 vs. 31.54–37.34 (P < 0.05). The clinical pregnancy rates in female age <35 vs. 35–39 vs. ≥40 years were 36.97–40.70 vs. 32.74–33.42 vs. 21.08–31.34, respectively (P < 0.001), and the percentage values of multifetal pregnancy rate were 18.75 vs. 13.30 and 13.69, respectively (P < 0.001). There were increasing preimplantation genetic screening (PGS) cycles, with the percentage of the clinical pregnancy rate (25.90–42.63, P < 0.05). The clinical pregnancy rates in medium-sized ART centers (100–300 cycles per year) vs. in small and large centers were 30.79–41.14 vs. 28.01–34.04 and 8.70–40.35, respectively (P < 0.001). Trends of increasing percentage of ART birth rate to total birth rate ratio were 0.24–0.34 (P < 0.05).ConclusionsThere were higher clinical pregnancy rates in frozen-thawed cycles. Higher multifetal pregnancy rate and clinical pregnancy rate were also found in younger females. There were increasing uses of ICSI and PGS. A trend toward increasing ART birth to total birth ratio was observed.

Download Full-text

Short ejaculatory abstinence in normozoospermic men is associated with higher clinical pregnancy rates in sub-fertile couples undergoing intra-cytoplasmic sperm injection in assisted reproductive technology: A retrospective analysis of 1691 cycles

Journal of Human Reproductive Sciences ◽

10.4103/jhrs.jhrs_235_20 ◽

2021 ◽

Vol 14 (3) ◽

pp. 273

Author(s):

Sweta Gupta ◽

VikramJ Singh ◽

Ashish Fauzdar ◽

Kamta Prasad ◽

Ajay Srivastava ◽

...

Keyword(s):

Retrospective Analysis ◽

Assisted Reproductive Technology ◽

Reproductive Technology ◽

Pregnancy Rates ◽

Clinical Pregnancy ◽

Intra Cytoplasmic Sperm Injection ◽

Clinical Pregnancy Rates ◽

Ejaculatory Abstinence

Download Full-text

Frozen-thawed embryo transfers in natural cycles with spontaneous ovulation are associated with increased clinical pregnancy rates

10.26226/morressier.573c1512d462b80296c98557 ◽

2016 ◽

Author(s):

marie montagut

Keyword(s):

Pregnancy Rates ◽

Clinical Pregnancy ◽

Clinical Pregnancy Rates ◽

Natural Cycles

Download Full-text

Impact of conscious sedation during oocyte retrieval on clinical pregnancy rate in assisted reproductive technology? An equivalence study in France.

10.26226/morressier.5912d9e8d462b80292386bc7 ◽

2017 ◽

Author(s):

Nicolas BOURGON

Keyword(s):

Pregnancy Rate ◽

Assisted Reproductive Technology ◽

Conscious Sedation ◽

Oocyte Retrieval ◽

Reproductive Technology ◽

Clinical Pregnancy ◽

Clinical Pregnancy Rate

Download Full-text

Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany

Reproductive Biology and Endocrinology ◽

10.1186/s12958-021-00768-3 ◽

2021 ◽

Vol 19 (1) ◽

Author(s):

Klaus F. Bühler ◽

Robert Fischer ◽

Patrice Verpillat ◽

Arthur Allignol ◽

Sandra Guedes ◽

...

Keyword(s):

Assisted Reproductive Technology ◽

Live Birth ◽

Pregnancy Loss ◽

Follicle Stimulating Hormone ◽

Reproductive Technology ◽

Clinical Pregnancy ◽

Human Menopausal Gonadotropin ◽

Ongoing Pregnancy ◽

Complete Cycle ◽

Significant Difference

Abstract Background This study compared the effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa; GONAL-f®) with urinary highly purified human menopausal gonadotropin (hMG HP; Menogon HP®), during assisted reproductive technology (ART) treatments in Germany. Methods Data were collected from 71 German fertility centres between 01 January 2007 and 31 December 2012, for women undergoing a first stimulation cycle of ART treatment with r-hFSH-alfa or hMG HP. Primary outcomes were live birth, ongoing pregnancy and clinical pregnancy, based on cumulative data (fresh and frozen-thawed embryo transfers), analysed per patient (pP), per complete cycle (pCC) and per first complete cycle (pFC). Secondary outcomes were pregnancy loss (analysed per clinical pregnancy), cancelled cycles (analysed pCC), total drug usage per oocyte retrieved and time-to-live birth (TTLB; per calendar week and per cycle). Results Twenty-eight thousand six hundred forty-one women initiated a first treatment cycle (r-hFSH-alfa: 17,725 [61.9%]; hMG HP: 10,916 [38.1%]). After adjustment for confounding variables, treatment with r-hFSH-alfa versus hMG HP was associated with a significantly higher probability of live birth (hazard ratio [HR]-pP [95% confidence interval (CI)]: 1.10 [1.04, 1.16]; HR-pCC [95% CI]: 1.13 [1.08, 1.19]; relative risk [RR]-pFC [95% CI]: 1.09 [1.05, 1.15], ongoing pregnancy (HR-pP [95% CI]: 1.10 [1.04, 1.16]; HR-pCC [95% CI]: 1.13 [1.08, 1.19]; RR-pFC [95% CI]: 1.10 [1.05, 1.15]) and clinical pregnancy (HR-pP [95% CI]: 1.10 [1.05, 1.14]; HR-pCC [95% CI]: 1.14 [1.10, 1.19]; RR-pFC [95% CI]: 1.10 [1.06, 1.14]). Women treated with r-hFSH-alfa versus hMG HP had no statistically significant difference in pregnancy loss (HR [95% CI]: 1.07 [0.98, 1.17], were less likely to have a cycle cancellation (HR [95% CI]: 0.91 [0.84, 0.99]) and had no statistically significant difference in TTLB when measured in weeks (HR [95% CI]: 1.02 [0.97, 1.07]; p = 0.548); however, r-hFSH-alfa was associated with a significantly shorter TTLB when measured in cycles versus hMG HP (HR [95% CI]: 1.07 [1.02, 1.13]; p = 0.003). There was an average of 47% less drug used per oocyte retrieved with r-hFSH-alfa versus hMG HP. Conclusions This large (> 28,000 women), real-world study demonstrated significantly higher rates of cumulative live birth, cumulative ongoing pregnancy and cumulative clinical pregnancy with r-hFSH-alfa versus hMG HP.

Download Full-text

The Potential Applications of Peroxisome Proliferator-Activated ReceptorδLigands in Assisted Reproductive Technology

PPAR Research ◽

10.1155/2008/794814 ◽

2008 ◽

Vol 2008 ◽

pp. 1-6 ◽

Cited By ~ 1

Author(s):

Jaou-Chen Huang

Keyword(s):

Assisted Reproductive Technology ◽

Reproductive Function ◽

Reproductive Technology ◽

Embryonic Cell ◽

Preimplantation Embryos ◽

Peroxisome Proliferator ◽

Peroxisome Proliferator Activated Receptor ◽

Potential Applications ◽

And Function

Peroxisome proliferator-activated receptorδ(PPARδ, also known as PPARβ) has ubiquitous distribution and extensive biological functions. The reproductive function of PPARδwas first revealed in the uterus at the implantation site. Since then, PPARδand its ligand have been discovered in all reproductive tissues, including the gametes and the preimplantation embryos. PPARδin preimplantation embryos is normally activated by oviduct-derived PPARδligand. PPARδactivation is associated with an increase in embryonic cell proliferation and a decrease in programmed cell death (apoptosis). On the other hand, the role of PPARδand its ligand in gamete formation and function is less well understood. This review will summarize the reproductive functions of PPARδand project its potential applications in assisted reproductive technology.

Download Full-text